Keros Therapeutics, Inc. (KROS)
10.78
-0.25
(-2.27%)
USD |
NASDAQ |
Aug 24, 16:00
10.79
+0.01
(+0.09%)
Pre-Market: 20:00
Keros Therapeutics Price to Book Value : 0.8148 for Aug. 24, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 0.8148 |
| August 21, 2026 | 0.8337 |
| August 20, 2026 | 0.8276 |
| August 19, 2026 | 0.839 |
| August 18, 2026 | 0.8019 |
| August 17, 2026 | 0.7921 |
| August 14, 2026 | 0.7634 |
| August 13, 2026 | 0.8057 |
| August 12, 2026 | 0.8465 |
| August 11, 2026 | 0.8042 |
| August 10, 2026 | 0.808 |
| August 07, 2026 | 0.8428 |
| August 06, 2026 | 0.805 |
| August 05, 2026 | 0.7555 |
| August 04, 2026 | 0.7747 |
| August 03, 2026 | 0.7642 |
| July 31, 2026 | 0.7611 |
| July 30, 2026 | 0.7725 |
| July 29, 2026 | 0.7536 |
| July 28, 2026 | 0.7611 |
| July 27, 2026 | 0.7717 |
| July 24, 2026 | 0.7604 |
| July 23, 2026 | 0.7664 |
| July 22, 2026 | 0.7717 |
| July 21, 2026 | 0.7989 |
| Date | Value |
|---|---|
| July 20, 2026 | 0.8019 |
| July 17, 2026 | 0.8042 |
| July 16, 2026 | 0.8019 |
| July 15, 2026 | 0.8337 |
| July 14, 2026 | 0.7989 |
| July 13, 2026 | 0.839 |
| July 10, 2026 | 0.8919 |
| July 09, 2026 | 0.9093 |
| July 08, 2026 | 0.8821 |
| July 07, 2026 | 0.8806 |
| July 06, 2026 | 0.8337 |
| July 02, 2026 | 0.8511 |
| July 01, 2026 | 0.8224 |
| June 30, 2026 | 0.8087 |
| June 29, 2026 | 0.7551 |
| June 26, 2026 | 0.7592 |
| June 25, 2026 | 0.7192 |
| June 24, 2026 | 0.7544 |
| June 23, 2026 | 0.7599 |
| June 22, 2026 | 0.7586 |
| June 18, 2026 | 0.7358 |
| June 17, 2026 | 0.7192 |
| June 16, 2026 | 0.6929 |
| June 15, 2026 | 0.7074 |
| June 12, 2026 | 0.7012 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Incyte Corp. | 4.054 |
| Nurix Therapeutics, Inc. | 6.766 |
| ACADIA Pharmaceuticals, Inc. | 3.906 |
| Alnylam Pharmaceuticals, Inc. | 23.31 |
| Anika Therapeutics, Inc. | 2.080 |
Price to Book Value Related Metrics
| PS Ratio | 19.25 |
| Price | 10.78 |
| Earnings Yield | -34.32% |
| Market Cap | 213.74M |